A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE
Conditions
Sjögren's Syndrome
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Sydney Eye Hospital, Sydney, New South Wales, Australia
Univ of New South Wales, Sydney, New South Wales, Australia
OTA, Brisbane, Queensland, Australia
Queensland University of Technology, Brisbane, Queensland, Australia
Contact: Study coordinator (Katie Clinical Trial Coordinator) · katie.edwards@qut.edu.au · +61 07 3138 6154University of the Sunshine Coast, Maroochydore, Queensland, Australia
University of Melbourne, Melbourne, Victoria, Australia